Robotic knee surgery platform developer OmniLife Science said today it began testing on its OmniBotics active spacer robotic tissue balancing device at 3 US sites after having won FDA 510(k) clearance in September.
The Raynham, Mass.-based company said its OmniBotics active spacer is designed to allow surgeons performing total knee surgeries to quantitatively manage the soft tissue envelope during the procedure, and can be combined with the company’s OmniBotics system for a customized procedure from a skeletal and tissue-based perspective.
